The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCap-xx Regulatory News (CPX)

Share Price Information for Cap-xx (CPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.078
Bid: 0.076
Ask: 0.08
Change: -0.004 (-4.88%)
Spread: 0.004 (5.263%)
Open: 0.082
High: 0.082
Low: 0.078
Prev. Close: 0.082
CPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

28 Feb 2023 07:00

RNS Number : 2197R
CAP-XX Limited
28 February 2023
 

Dissemination of a Regulatory Announcement that contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310

 

28 February 2023

 

 

CAP-XX Limited

("CAP-XX" or the "Company")

 

Interim Results for the half-year ended 31 December 2022

 

 

CAP-XX Limited, a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems, announces its interim results for the half-year ended 31 December 2022.

 

Key highlights

 

· Total revenue down 34% on corresponding half-year to A$1.6m

 

· Product sales down 40% on corresponding half-year to A$1.4m. To our knowledge the Company has not lost any significant business to competitors

 

· Sales order book at 31/12/22 was 47% higher than at beginning of July 2022 and 85% higher than at August 2022

 

· Sales pipeline continues to increase - now in excess of US$65 million p.a.

 

· Continuing to add new distributors to broaden sales channels

 

· Performance of Seven Hills manufacturing facility continues to improve

 

· A$187k in royalty/ licence income recognised in period (corresponding half-year A$0)

 

· Adjusted EBITDA was a loss ofA$966k (2021: Adjusted EBITDA loss ofA$305k)

 

· CAP-XX court case against Maxwell for patent infringement postponed by the judge to 24 July 2023, due to judge's case load. Notwithstanding the delay, the Board remains confident of success in this action

 

· The Board has now formed the view that it is unlikely the Company can obtain litigation funding on acceptable terms

 

· Cash reserves as at 31 December 2022 were A$0.5 million with no debt. In addition, the Company has an unused line of credit of approximately A$1.7m.

 

* Adjusted EBITDA excludes patent infringement costs

 

Anthony Kongats, CEO of CAP-XX said:

"We are disappointed by the large drop in product sales for the first half of this financial year however the Board is confident the Company will see a rebound in the second half of this financial year. Its optimism is based on recent customer orders received, recent design wins and feedback from the market. The performance of our Seven Hills facility continues to improve where reject rates over the past six months improved by nine percentage points on the previous six months. We expect to see further improvements moving forward which will in turn improve gross margins. We look forward to a much stronger sales performance in the second half of the year."

Electronic copies of CAP-XX's interim results for the half-year ended 31 December 2022 will shortly be available from the Company's website: www.cap-xx.com.

 

 

For further information contact:

 

CAP-XX Limited

Anthony Kongats (Chief Executive Officer) +61 (0) 2 9428 0139

 

Kreab (Financial PR)

Robert Speed +44 (0) 20 7074 1800

 

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Alex Brearley (Corporate Finance) +44 (0) 20 3328 5656

Tony Quirke (Sales and Corporate Broking)

 

Cenkos Securities plc (Joint Broker)

Neil McDonald / Pearl Kellie +44 (0) 13 1220 6939

 

 

 

More information is available at www.cap-xx.com

 

Notes to Editors:

 

CAP-XX (LSE: CPX) is a world leader in the design and manufacture of thin, flat supercapacitors and energy management systems used in portable and small-scale electronic devices, and to an increasing extent, in larger applications such as automotive and renewable energy. The unique feature of CAP-XX supercapacitors is their very high power density and high energy storage capacity in a space-efficient prismatic package. These attributes are essential in power-hungry consumer and industrial electronics, and deliver similar benefits in automotive and other transportation applications. For more information about CAP-XX, visit www.cap-xx.com

 

Chairman's statement

 

As foreshadowed in the FY2021/22 results and at the AGM, the current financial year has started slower than expected. This was due to several influences including: industry wide supply chain bottlenecks, especially in China, a global shortage of integrated circuits affecting customer order volumes and increasing pessimism over the state of the global economy. The flow on effects of factory closures in Asia which lead to delays in shipments of critical components has resulted in delayed sales of supercapacitors. Concerns about the ongoing war in Europe and a possible recession have also caused some customers to reduce or defer their purchase orders as they look to reduce their inventory levels and delay new product launches. The greatest falls were in the Asian region which are believed to be due to two main factors. First, some customers which saw a boom in demand during COVID are now seeing demand falling as customer demand flattens. It is currently unclear whether this is a short-term correction or if it will take longer for demand to recover. Second, several customers had placed larger and longer time frame orders during COVID while components were in critical shortage. Now that component availability is returning to pre-COVID levels, customers are reducing their inventory levels before reordering. Based on anecdotal evidence, we believe that the drop in our H1 sales is similar to that which our competitors and other component players in similar markets have experienced. To our knowledge, no significant business has been lost to a competitor.

Total revenue was A$1.61 million down 34% on the same period in the prior year (A$2.4 million). Total product sales for the half year were A$1.4 million down 40% on the same period in the prior year (A$2.6 million). The EBITDA loss for the six months ended 31 December 2022 was A$966k. This compared to an EBITDA loss of A$305k for the corresponding period last year. During the period, A$187k in royalty income was received (A$0 in the corresponding half year). Gross margin increased from 34% overall to 37%. Operating expenses increased by 10% due to increased patent filing costs and resumption of overseas travel. As at 31 December 2022, cash reserves were A$495k with no debt and before the Company utilised its existing line of credit.

Despite the slower than expected start to the year, the Board remains optimistic about the short and long-term growth prospects of the Company. The order book is improving and at 31 December 2022 was 47% higher than at the start of the current financial year and 85% higher than its low point at the end of August 2022, with a significant portion of the increase coming from those customers whose sales in the first six months were less than expected.

Furthermore, the sales pipeline has increased by 30% to more than US$65 million compared to 12 months ago. The growth in the sales pipeline continues to be well spread across a number of different Internet of things "IoT") related market segments. At the same time, the Company achieved several new design wins in energy harvesting, smart meters and industrial products. The Board believes that demand for both non-cellular and cellular IoT devices will continue to grow rapidly. Based on past experience, these new design wins can take between six months and five years to move into mass production with an average being around two years.

 

During the first half, the Company launched three new product families: the Ioxus modules; the 5mm ultra-thin cylindrical supercapacitor and coin cell supercapacitors for Real Time Clock (RTC) applications. The Company has already made its first sales of Ioxus modules and coin cell supercapacitors. Over the next 12 months, we expect sales of these new products to grow substantially.

 

Simultaneously, as part of its stated strategy, the Company has continued to add new broadline and speciality distributors to broaden our sales access to different application and geographic markets.

 

Production at Seven Hills continues to improve. Reject rates of products made at Seven Hills decreased by a further nine percentage points from the previous six months. Reject rates are expected to decrease further as production runs increases. The current output is exceeding customer demand and key performance metrics are tracking in line with our expectations. As expected at this stage of production, the Company is continuing to address small incremental improvements and is hiring additional staff for the Seven Hills facility. We expect to see steady improvement over the remainder of 2023. The Board is confident that target outputs and other key performance metrics will be reached as expected. The Company continues to make good progress in readying production for Continental and its design wins due to start in 2024. The commissioning of the fourth production line, the DMH line, is expected to be completed around the end of 2023, with production expected to start in the fourth quarter of 2023 or early 2024 as time and resources allow and subject to customer demand.

After several years of development, the Board expects several new products to be released in 2023. The first of these is the DMV 3V single cell supercapacitor which was launched in February 2023. The DMV is targeted at applications using 3V coin cell batteries and energy harvesting applications that do not use a battery at all. Several new patents are also expected to be filed covering new market applications. In addition to these activities, CAP-XX R&D continues to make progress in ways to reduce supercapacitor production costs, increase cell voltage and improve product performance through the use of new materials. The Company is continuing discussions with other companies regarding licencing and partnering opportunities.

 

Licensing remains an important revenue stream for CAP-XX and the Company continues to defend its intellectual property. CAP-XX continues to vigorously pursue its patent infringement action against Maxwell Technologies, now a wholly owned subsidiary of Tesla Inc. and other companies. Due to his case load, the judge in the Maxwell case has moved the trial date to 24th July 2023. The effect of this is that the Company's current level of legal expenses has greatly reduced while also delaying the receipt of any future settlement. The Board remains optimistic of the Company's prospects in this matter. However, while the Board had previously reported that it expected to secure litigation funding for the Maxwell case, the Board now believes that it is no longer able to secure such funding on acceptable terms to the Company. As such, the Board is reviewing options for how to continue funding this litigation alongside the Company ongoing cash requirements.

The Board is confident that the short-term fall in sales will be reversed over the next six months and the longer-term growth of sales for IoT devices and the new Seven Hills production lines will transform the Company's revenue position with a consequential benefit to cash flow and the cash position of the Company. Subject to the issues already discussed, the Board continues to strive for the Company to be EBITDA and cashflow positive in the next financial year.

 

 

 

Patrick Elliott

Chairman

 

CAP-XX Limited

Consolidated statement of profit or loss

For the half-year ended 31 December 2022

 

Consolidated

 

 

Half-year 2022

Half-year 2021

 

 

 

Currency: Australian Dollars

 

$

$

Revenue from sale of goods and services

 

1,613,684

2,428,416

Cost of sale of goods and services

(1,015,774)

(1,604,829)

Gross margin (loss) on sale of goods and services

597,910

823,587

Other revenue

 

456

3,120

Other income

 

1,103,384

 

1,169,442

General and administrative expenses

(1,791,515)

(1,484,788)

Process and engineering expenses

(676,629)

(490,505)

Selling and marketing expenses

(407,085)

(392,564)

Research and Development expenses

(900,223)

(729,501)

Share based payments

(387,326)

(435,053)

Other expenses

(111,800)

(200,186)

(Loss) before income tax

(2,572,828)

(1,736,448)

 

 

 

Income tax benefit/(expense)

-

-

Net loss after income tax for the half year

(2,572,828)

(1,736,448)

 

 

 

(Loss) attributable to members of CAP-XX Limited

(2,572,828)

(1,736,448)

 

 

 

 

Loss per share attributable to the ordinary equity holders of the company

Cents

Cents

Basic loss per share

(0.57)

(0.35)

Diluted loss per share

(0.57)

(0.35)

 

 

 

 

 

 

 

CAP-XX Limited

Consolidated statement of comprehensive income

For the half year ended 31 December 2022

 

 

Consolidated

 

 

 

2022

2021

 

Currency: Australian Dollars

 

$

$

 

Loss for the half year

(2,572,828)

(1,736,448)

 

Other comprehensive income

 

Items that may be reclassified subsequently to profit or loss

 

 

 

Exchange differences on translation of foreign operations

(5,108)

(33,476)

 

Other comprehensive loss for the half year, net of tax

(5,108)

(33,476)

 

Total comprehensive loss for the half year attributable to owners of CAP-XX Limited

(2,577,936)

(1,769,924)

 

 

 

 

 

 

 

 

CAP-XX Limited

Consolidated statement of financial position

As at 31 December 2022

 

 

Consolidated

 

 

31 December 2022

31 December 2021

 

 

 

 

 

 

Currency: Australian Dollars

 

 

$

$

 

 

ASSETS

 

Current assets

 

Cash and cash equivalents

494,839

5,055,747

 

Receivables

567,760

1,123,331

 

Inventories

2,300,272

1,076,799

 

Other

1,097,305

1,203,308

 

Total current assets

 

4,460,176

8,459,185

 

 

Non-current assets

 

Property, plant and equipment

2,626,643

2,872,517

 

Right of Use Assets

2,372,360

2,727,890

 

Other

204,808

397,063

 

Total non-current assets

 

5,203,811

5,997,470

 

 

TOTAL ASSETS

 

 

9,663,987

14,456,655

 

 

LIABILITIES

 

Current liabilities

 

Payables

1,035,285

1,050,141

 

Lease Liabilities

205,128

134,546

 

 

Provisions

801,016

795,164

 

Total current liabilities

2,041,429

1,979,851

 

 

Non-current liabilities

 

Lease Liabilities

2,095,836

2,348,248

 

Provisions

770,957

761,529

 

Total non-current liabilities

2,866,793

3,109,777

 

 

TOTAL LIABILITIES

 

 

4,908,222

5,089,628

 

 

 

 

 

NET ASSETS

 

 

4,755,765

9,367,027

 

 

 

 

EQUITY

 

Contributed equity

 

114,615,217

114,511,789

 

Reserves

7,895,991

6,835,441

 

Accumulated losses

(117,755,443)

(111,980,203)

 

TOTAL EQUITY

 

 

4,755,765

9,367,027

 

 

 

 

 

 

 

 

CAP-XX Limited

Consolidated statements of changes in equity

For the half-year ended 31 December 2022

Consolidated

 

 

Contributed

Equity

$

Reserve

$

Accumulated losses

$

Total

$

 

 

 

Balance at 1 July 2021

108,766,530

6,433,864

(110,243,755)

4,956,639

Loss for the period as reported in the 2021 financial statements

(4,938,860)

(4,938,860)

 

Other comprehensive loss 

 

- 

(53,490)

-

 

(53,490)

Transactions with owners in their capacity as owners:

Contributions of equity, net of transaction costs and tax

5,745,259

5,745,259

Employee share options - value of employee services

 

 

-

1,133,399

-

1,133,399

Balance at 30 June 2022

 

114,511,789

7,513,773

(115,182,615)

 6,842,948

 

Profit for the period as reported in the 2022 interim financial statements

 

- 

-

(2,572,828)

(2,572,828)

Other comprehensive income 

- 

(5,108)

-

 

(5,108)

Transactions with owners in their capacity as owners:

Contributions of equity, net of transaction costs and tax

103,428

 - 

 - 

103,428

Employee share options - value of employee services

-

387,326

-

387,326

Balance at 31 December 2022

114,615,217

7,895,991

 (117,755,443)

4,755,765

 

 

 

 

CAP-XX Limited

Consolidated Statement of Cash Flows

For the half-year ended 31 December 2022

 

Consolidated

 

Half-year 2022

Half-year 2021

 

 

 

Currency: Australian Dollars

 

$

$

Cash flows from operating activities

Receipts from customers (inclusive of goods and services tax)

2,180,265

2,565,957

Payments to suppliers and employees (inclusive of goods and services tax)

(5,322,963)

(5,191,497)

(3,142,698)

(2,625,540)

Tax credit received

2,043,384

3,211,314

Interest received

456

3,121

Net cash (outflow)/ inflow from operating activities

(1,098,858)

588,895

Cash flows from investing activities

Payments for property, plant and equipment

(119,337)

(27,532)

Net cash (outflow) from investing activities

(119,337)

(27,532)

 

 

Cash flows from financing activities

Proceeds from issue of shares

103,428

5,745,259

Advance payments

-

(1,400,000)

Net cash inflow from financing activities

103,428

4,345,259

Net (decrease)/ increase in cash and cash equivalents

(1,114,767)

4,906,622

Cash and cash equivalents at the beginning of the half-year

1,614,714

182,601

Effects of exchange rate changes on cash and cash equivalents

(5,108)

(33,476)

Cash and cash equivalents at the end of the half-year

 

 

494,839

5,055,747

 

 

 

 

 

 

 

This general purpose interim financial report, for the half-year reporting period ended 31 December 2022, has been prepared in accordance with Australian equivalents to International Financial Reporting Standards (AIFRSs), other authoritative pronouncements of the Australian Accounting Standards Board, Urgent Issues Group Interpretations and the Corporations Act 2001. This general purpose interim financial report, for the half-year reporting period ended 31 December 2022, is unaudited.

 

 

-ENDS-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR EADAXAFLDEAA
Date   Source Headline
1st May 202411:08 amRNSHolding(s) in Company
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company
3rd Nov 20239:05 amRNSResult of AGM and Directorate Change
3rd Nov 20237:05 amRNSAGM Trading Update
26th Oct 20232:05 pmRNSHolding(s) in Company
13th Oct 20239:45 amRNSNotice of AGM
4th Oct 20237:00 amRNSExpansion of sales operations
29th Sep 20237:00 amRNSAudited results for the year ended 30 June 2023
14th Sep 202312:29 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSPre-close Trading Update and Notice of Results
31st Jul 20239:53 amRNSHolding(s) in Company
18th Jul 202310:27 amRNSUpdate on Patent Infringement
30th Jun 20235:00 pmRNSTotal Voting Rights
13th Jun 20237:00 amRNSHolding(s) in Company
9th Jun 20237:53 amRNSAppointment of Chief Executive Officer
8th Jun 20238:38 amRNSHolding(s) in Company
8th Jun 20237:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.